FASN and fatty liver disease: In addition, hepatic FASN deficiency ameliorated hepatic steatosis to a lesser extent in Mc4r-KO mice than in ob/ob mice, as assessed on the basis of hepatic triglyceride content (70% versus 96% inhibition) (Figure 1E and Figure 6E).